Dr. Michael T. Milano, MD

Dr. Milano practices at Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center.

Dr. Milano's NPI, 1164452314, was assigned on July 4, 2006. Dr. Milano graduated from University of Rochester Medical Center in 2000. Dr. Milano holds New York license 235177.

Dr. Milano's primary practice is Strong Memorial Hospital, at 601 Elmwood Ave, Rochester, NY 14642 in Monroe County. The practice phone is (585) 275-2121.

Dr. Milano's primary practice is Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center. Dr. Milano is also affiliated with Highland Hospital. The medical group on file is Noyes Health. Dmand AI also links Dr. Milano to 3 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Milano practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Milano's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Milano is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Milano's licenses on file in 2 states: New York and Illinois.

Dmand AI lists bone cancer radiation, brain cancer radiation, brain tumor radiation and lung cancer radiation among the conditions Dr. Milano treats.

CMS data shows 670 Medicare services from Dr. Milano across 14 procedure codes in 2024, for 107 Medicare patients. Medicare paid $51,411 for them.

CMS counts 107 Medicare patients who saw Dr. Milano in 2024. The largest group is 65 to 74, with 45 patients. 67% of them have high cholesterol, and 66% have high blood pressure. 21% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Milano's median patient age at 69, with 51% women.

In 2024, Dr. Milano wrote 50 Medicare Part D claims for 26 patients. 90% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $289 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Milano for performance year 2024, reported as part of a group. Dr. Milano accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Milano as offering telehealth.

Dmand AI links 146 papers to Dr. Milano, published from 2006 to 2025. 2020 was the busiest year, with 10. The most frequent topics are Radiosurgery, Brain Neoplasms and Radiotherapy Dosage. Dr. Milano has published most often in Int J Radiat Oncol Biol Phys. Dr. Milano's most frequent co-authors are Paul G. Okunieff, MD, Kenneth Yukio Usuki, MD and Lawrence B. Marks, MD.

Dmand AI links Dr. Milano to 2 clinical trials. Conditions studied include Neoplasm Metastasis and Neoplastic Processes. University of Rochester sponsors the most, 2.

CMS Open Payments shows 8 general payments to Dr. Milano from 4 drug and device companies from 2017 to 2020. Consulting fees make up the largest share, 94% of the total. AstraZeneca Pharmaceuticals LP paid the most, $6,040.

Dmand AI lists 1 award for Dr. Milano, most recently CMS Stage 1 EHR in 2012.

Dr. Milano graduated from University of Rochester Medical Center in 2000.

Dr. Milano is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.